Crewe Advisors’s Kyntra Bio KYNB Stock Holding History

Crewe Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7	Closed	-$2K	–	1111
2022 Q3	$2K	Hold	7	–	–	﹤0.01%	1035
2022 Q2	$2K	Buy	+7	New	+$1.79K	﹤0.01%	971

Other funds holding KYNB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Crewe Advisors's KYNB Position: Q4 2022 in Review

Crewe Advisors sold out of Kyntra Bio (KYNB) in Q4 2022, closing a stake of 7 shares — an estimated $2K sold.

Crewe Advisors first reported a position in KYNB in Q2 2022 and held it in 2 quarters. The position peaked at $2K in Q3 2022. 143 funds tracked by Wall St. Rank hold KYNB as of Q4 2022.

Crewe Advisors reported no remaining Kyntra Bio position as of Q4 2022 after selling out during the quarter.
Crewe Advisors sold 7 Kyntra Bio shares in Q4 2022, an estimated $2K.
Crewe Advisors first reported a position in Kyntra Bio in Q2 2022 and held it in 2 quarters.
Crewe Advisors's Kyntra Bio position peaked at $2K in Q3 2022.
143 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2022.

Based on Crewe Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.